Baseline and cumulative incidence of bone metastases and SREs is high in patients with EGFR+ metastatic NSCLC treated with first- and second-generation EGFR TKIs, and therefore, better treatment options are necessary.11 Here, EGFR is linked to non-small cell lung carcinoma.